ResearcherJohns Hopkins UniversityActive in the last 2 years
Kevin J Yarema
Matched on ORCID iD 0000-0002-4279-1459; OpenAlex author ID A5067156333; NIH RePORTER profile ID 7736369. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 3)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 4
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 grant · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Profiling the pancreatic cancer secretome with metabolic glycoengineering. Last author DOI 10.1016/j.jbc.2026.111243↗
- Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic c… Last author DOI 10.18632/oncotarget.11582↗
- Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib. Last author DOI 10.1016/j.bmcl.2015.01.060↗
Grants 1
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christian Agatemor · 1 shared paper, 2026 · strength 0.26
- Kris Dammen‐Brower · 1 shared paper, 2026 · strength 0.26
- Guanshu Liu · 1 shared paper, 2026 · strength 0.26
- Mohit Philip Mathew · 2 shared papers, 2015–2016 · strength 0.12
- Paper Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth facto… DOI 10.18632/oncotarget.11582↗
- Paper Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib an… DOI 10.1016/j.bmcl.2015.01.060↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.